Analysts Set Anavex Life Sciences Corp (NASDAQ:AVXL) PT at $9.35
Anavex Life Sciences Corp (NASDAQ:AVXL) has earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $9.35.
Several equities analysts have recently weighed in on AVXL shares. Dawson James started coverage on Anavex Life Sciences in a report on Wednesday, July 24th. They set a “buy” rating and a $16.00 price target for the company. Zacks Investment Research upgraded Anavex Life Sciences from a “sell” rating to a “hold” rating and set a $3.75 price target for the company in a report on Monday, July 8th. Janney Montgomery Scott started coverage on Anavex Life Sciences in a report on Tuesday, June 18th. They set a “buy” rating and a $10.00 price target for the company. ValuEngine downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd. Finally, Roth Capital restated a “buy” rating on shares of Anavex Life Sciences in a report on Thursday, May 23rd.
Large investors have recently modified their holdings of the company. Deutsche Bank AG bought a new position in shares of Anavex Life Sciences during the fourth quarter valued at $28,000. Wedbush Securities Inc. purchased a new stake in shares of Anavex Life Sciences during the first quarter valued at $43,000. Hikari Power Ltd boosted its position in shares of Anavex Life Sciences by 17.6% during the first quarter. Hikari Power Ltd now owns 174,080 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 26,000 shares during the last quarter. B. Riley Financial Inc. purchased a new stake in shares of Anavex Life Sciences during the first quarter valued at $351,000. Finally, Virtu Financial LLC purchased a new stake in shares of Anavex Life Sciences during the first quarter valued at $152,000. Hedge funds and other institutional investors own 14.05% of the company’s stock.
Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, equities research analysts predict that Anavex Life Sciences will post -0.64 EPS for the current fiscal year.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Featured Article: Net Margin
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.